Similar Papers

Paper Title
Journal
Date
Author
Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
Christiane A Houde ... Clifton C Mo
Blood | VOL. 142
Christiane A Houde, et. al.Christiane A Houde ... Clifton C Mo
28 Nov 2023
Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.
Cristina Gasparetto ... Mohit Narang
Journal of Clinical Oncology | VOL. 35
Cristina Gasparetto, et. al.Cristina Gasparetto ... Mohit Narang
20 May 2017
Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study
Robert M Rifkin ... Habte A Yimer
Blood | VOL. 134
Robert M Rifkin, et. al.Robert M Rifkin ... Habte A Yimer
13 Nov 2019
Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Abby Statler ... Mikkael A Sekeres
Blood | VOL. 134
Abby Statler, et. al.Abby Statler ... Mikkael A Sekeres
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma.
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.